Clinical and Prognostic Effect of Plasma Fibrinogen in Renal Cell Carcinoma

A Meta-Analysis

Yuejun Tian, Mei Hong, Suoshi Jing, Xingchen Liu, Hanzhang Wang, Xinping Wang, Dharam Kaushik, Ronald Rodriguez, Zhiping Wang

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Background. Although numerous studies have shown that plasma fibrinogen is linked to renal cell carcinoma (RCC) risk, the consistency and magnitude of the effect of plasma fibrinogen are unclear. The aim of the study was to explore the association between plasma fibrinogen and RCC prognosis. Methods. An electronic search of Embase, PubMed/MEDLINE, and the Cochrane databases was performed to identify relevant studies published prior to June 1, 2016. Results. A total of 3744 patients with RCC from 7 published studies were included in the meta-analysis. The prognostic and clinical relevance of plasma fibrinogen are evaluated in RCC patients. Statistical significance of the combined hazard ratio (HR) was detected for overall survival, cancer-specific survival, and disease-free survival. Our pooled results showed that elevated plasma fibrinogen was significantly associated with clinical stage and Fuhrman grading. The level of plasma fibrinogen was not found to be associated with tumor type and gender. Conclusions. Elevated plasma fibrinogen is a strong indicator of poorer prognosis of patients with RCC, whereas the plasma fibrinogen is not significantly associated with tumor type. Therefore, plasma fibrinogen could be used in patients with RCC for risk stratification and decision providing a proper therapeutic strategy.

Original languageEnglish (US)
Article number9591506
JournalBioMed Research International
Volume2017
DOIs
StatePublished - 2017

Fingerprint

Renal Cell Carcinoma
Fibrinogen
Meta-Analysis
Cells
Plasmas
Tumors
Neoplasms
Survival
PubMed
MEDLINE
Disease-Free Survival
Hazards
Databases

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Clinical and Prognostic Effect of Plasma Fibrinogen in Renal Cell Carcinoma : A Meta-Analysis. / Tian, Yuejun; Hong, Mei; Jing, Suoshi; Liu, Xingchen; Wang, Hanzhang; Wang, Xinping; Kaushik, Dharam; Rodriguez, Ronald; Wang, Zhiping.

In: BioMed Research International, Vol. 2017, 9591506, 2017.

Research output: Contribution to journalReview article

Tian, Yuejun ; Hong, Mei ; Jing, Suoshi ; Liu, Xingchen ; Wang, Hanzhang ; Wang, Xinping ; Kaushik, Dharam ; Rodriguez, Ronald ; Wang, Zhiping. / Clinical and Prognostic Effect of Plasma Fibrinogen in Renal Cell Carcinoma : A Meta-Analysis. In: BioMed Research International. 2017 ; Vol. 2017.
@article{9b10974f2b2646d1b605433d87fc4807,
title = "Clinical and Prognostic Effect of Plasma Fibrinogen in Renal Cell Carcinoma: A Meta-Analysis",
abstract = "Background. Although numerous studies have shown that plasma fibrinogen is linked to renal cell carcinoma (RCC) risk, the consistency and magnitude of the effect of plasma fibrinogen are unclear. The aim of the study was to explore the association between plasma fibrinogen and RCC prognosis. Methods. An electronic search of Embase, PubMed/MEDLINE, and the Cochrane databases was performed to identify relevant studies published prior to June 1, 2016. Results. A total of 3744 patients with RCC from 7 published studies were included in the meta-analysis. The prognostic and clinical relevance of plasma fibrinogen are evaluated in RCC patients. Statistical significance of the combined hazard ratio (HR) was detected for overall survival, cancer-specific survival, and disease-free survival. Our pooled results showed that elevated plasma fibrinogen was significantly associated with clinical stage and Fuhrman grading. The level of plasma fibrinogen was not found to be associated with tumor type and gender. Conclusions. Elevated plasma fibrinogen is a strong indicator of poorer prognosis of patients with RCC, whereas the plasma fibrinogen is not significantly associated with tumor type. Therefore, plasma fibrinogen could be used in patients with RCC for risk stratification and decision providing a proper therapeutic strategy.",
author = "Yuejun Tian and Mei Hong and Suoshi Jing and Xingchen Liu and Hanzhang Wang and Xinping Wang and Dharam Kaushik and Ronald Rodriguez and Zhiping Wang",
year = "2017",
doi = "10.1155/2017/9591506",
language = "English (US)",
volume = "2017",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Clinical and Prognostic Effect of Plasma Fibrinogen in Renal Cell Carcinoma

T2 - A Meta-Analysis

AU - Tian, Yuejun

AU - Hong, Mei

AU - Jing, Suoshi

AU - Liu, Xingchen

AU - Wang, Hanzhang

AU - Wang, Xinping

AU - Kaushik, Dharam

AU - Rodriguez, Ronald

AU - Wang, Zhiping

PY - 2017

Y1 - 2017

N2 - Background. Although numerous studies have shown that plasma fibrinogen is linked to renal cell carcinoma (RCC) risk, the consistency and magnitude of the effect of plasma fibrinogen are unclear. The aim of the study was to explore the association between plasma fibrinogen and RCC prognosis. Methods. An electronic search of Embase, PubMed/MEDLINE, and the Cochrane databases was performed to identify relevant studies published prior to June 1, 2016. Results. A total of 3744 patients with RCC from 7 published studies were included in the meta-analysis. The prognostic and clinical relevance of plasma fibrinogen are evaluated in RCC patients. Statistical significance of the combined hazard ratio (HR) was detected for overall survival, cancer-specific survival, and disease-free survival. Our pooled results showed that elevated plasma fibrinogen was significantly associated with clinical stage and Fuhrman grading. The level of plasma fibrinogen was not found to be associated with tumor type and gender. Conclusions. Elevated plasma fibrinogen is a strong indicator of poorer prognosis of patients with RCC, whereas the plasma fibrinogen is not significantly associated with tumor type. Therefore, plasma fibrinogen could be used in patients with RCC for risk stratification and decision providing a proper therapeutic strategy.

AB - Background. Although numerous studies have shown that plasma fibrinogen is linked to renal cell carcinoma (RCC) risk, the consistency and magnitude of the effect of plasma fibrinogen are unclear. The aim of the study was to explore the association between plasma fibrinogen and RCC prognosis. Methods. An electronic search of Embase, PubMed/MEDLINE, and the Cochrane databases was performed to identify relevant studies published prior to June 1, 2016. Results. A total of 3744 patients with RCC from 7 published studies were included in the meta-analysis. The prognostic and clinical relevance of plasma fibrinogen are evaluated in RCC patients. Statistical significance of the combined hazard ratio (HR) was detected for overall survival, cancer-specific survival, and disease-free survival. Our pooled results showed that elevated plasma fibrinogen was significantly associated with clinical stage and Fuhrman grading. The level of plasma fibrinogen was not found to be associated with tumor type and gender. Conclusions. Elevated plasma fibrinogen is a strong indicator of poorer prognosis of patients with RCC, whereas the plasma fibrinogen is not significantly associated with tumor type. Therefore, plasma fibrinogen could be used in patients with RCC for risk stratification and decision providing a proper therapeutic strategy.

UR - http://www.scopus.com/inward/record.url?scp=85010366717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010366717&partnerID=8YFLogxK

U2 - 10.1155/2017/9591506

DO - 10.1155/2017/9591506

M3 - Review article

VL - 2017

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 9591506

ER -